BRPI0819759A2 - Compositions and methods for inhibiting ds-rna-dependent protein kinase activation and tumor growth inhibition - Google Patents
Compositions and methods for inhibiting ds-rna-dependent protein kinase activation and tumor growth inhibitionInfo
- Publication number
- BRPI0819759A2 BRPI0819759A2 BRPI0819759-8A BRPI0819759A BRPI0819759A2 BR PI0819759 A2 BRPI0819759 A2 BR PI0819759A2 BR PI0819759 A BRPI0819759 A BR PI0819759A BR PI0819759 A2 BRPI0819759 A2 BR PI0819759A2
- Authority
- BR
- Brazil
- Prior art keywords
- rna
- inhibiting
- compositions
- methods
- tumor growth
- Prior art date
Links
- 102000001253 Protein Kinase Human genes 0.000 title 1
- 230000004913 activation Effects 0.000 title 1
- 230000001419 dependent effect Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108060006633 protein kinase Proteins 0.000 title 1
- 230000004614 tumor growth Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99013407P | 2007-11-26 | 2007-11-26 | |
US3737108P | 2008-03-18 | 2008-03-18 | |
PCT/US2008/078667 WO2009070378A1 (en) | 2007-11-26 | 2008-10-03 | Compositions and methods for inhibiting the activation of dsrna-dependent protein kinase and tumor growth inhibition |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0819759A2 true BRPI0819759A2 (en) | 2015-05-05 |
Family
ID=40099551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0819759-8A BRPI0819759A2 (en) | 2007-11-26 | 2008-10-03 | Compositions and methods for inhibiting ds-rna-dependent protein kinase activation and tumor growth inhibition |
Country Status (14)
Country | Link |
---|---|
US (1) | US20110077198A1 (en) |
EP (1) | EP2222297A1 (en) |
JP (1) | JP2011504879A (en) |
CN (1) | CN101868235A (en) |
AR (1) | AR069479A1 (en) |
AU (1) | AU2008329988A1 (en) |
BR (1) | BRPI0819759A2 (en) |
CA (1) | CA2706656A1 (en) |
CL (1) | CL2008003524A1 (en) |
MX (1) | MX2010005768A (en) |
RU (1) | RU2010126171A (en) |
TW (1) | TW200924744A (en) |
WO (1) | WO2009070378A1 (en) |
ZA (1) | ZA201004528B (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2381934A2 (en) * | 2008-12-23 | 2011-11-02 | Carmel - Haifa University Economic Corp Ltd. | Improving cognitive function |
CN102481009A (en) * | 2009-08-13 | 2012-05-30 | 雀巢产品技术援助有限公司 | Nutritional compositions including exogenous nucleotides |
CN102595936A (en) * | 2009-09-25 | 2012-07-18 | 雀巢产品技术援助有限公司 | Nutritional compositions including theanine and exogenous nucleotides |
AU2010310515B2 (en) * | 2009-10-22 | 2016-01-07 | University Of Southern California | Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment |
FR2970414B1 (en) * | 2011-01-14 | 2013-03-22 | Univ Paris Descartes | PREVENTIVE ACTION OF CITRULLINE ON THE SPONTANEOUS DEVELOPMENT OF TUMORS |
CN104053438A (en) * | 2011-10-18 | 2014-09-17 | 味之素株式会社 | Therapeutic agent for pancreatic cancer and/or biliary tract cancer |
JP2015500805A (en) * | 2011-11-29 | 2015-01-08 | ベイラー カレッジ オブ メディスンBaylor College Of Medicine | Cognitive enhancement method |
KR101909433B1 (en) * | 2011-12-02 | 2018-10-18 | 고쿠리츠다이가쿠호우진 야마구치 다이가쿠 | Agent for reducing adverse side effects of kinase inhibitor |
WO2014066426A1 (en) * | 2012-10-22 | 2014-05-01 | University Of Southern California | Methods and formulations promoting tissue/organ regeneration, longevity and healthspan |
KR101668074B1 (en) | 2015-02-12 | 2016-10-21 | 전북대학교산학협력단 | Composition comprising PKR inhibitor for preventing or treating severe bronchial asthma |
JOP20190146A1 (en) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | Amino acid compositions and methods for the treatment of liver diseases |
CN107158388B (en) * | 2017-07-11 | 2021-03-23 | 上海市第一人民医院 | Application of MIIP pS303 blocking agent in preparation of antitumor drugs |
CN111295187A (en) | 2017-08-14 | 2020-06-16 | 胺细拉健康公司 | Amino acid composition for treating liver diseases |
EP3810123A1 (en) | 2018-06-20 | 2021-04-28 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
WO2023208028A1 (en) * | 2022-04-29 | 2023-11-02 | 中国科学院分子细胞科学卓越创新中心 | Circular rna with 16 bp-26 bp double-stranded stem-loop structure for treating psoriasis or alzheimer's disease |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0577769A4 (en) * | 1991-03-29 | 1994-06-01 | Us Commerce | Pharmaceutical compositions and methods for preventing skin tumor formation and causing regression of existing tumors |
US6326466B1 (en) * | 1996-07-30 | 2001-12-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Double-stranded RNA dependent protein kinase derived peptides to promote proliferation of cells and tissues in a controlled manner |
US6326465B1 (en) * | 1997-02-24 | 2001-12-04 | The Johns Hopkins University | Immunomodulatory polypeptides derived from the invariant chain of MHC class II |
US6864061B2 (en) * | 2000-09-14 | 2005-03-08 | Genetrol Biotherapeutics, Inc. | Method for screening compounds for anti-inflammatory activity |
WO2007013696A1 (en) * | 2005-07-29 | 2007-02-01 | Torii Pharmaceutical Co., Ltd. | Anti-tumor agent comprising 6'-amidino-2'-naphthyl4- guanidinobenzoate or salt thereof |
BRPI0619179A2 (en) * | 2005-11-30 | 2011-09-13 | Nestec Sa | Methods For Treating Muscle Loss |
US20100247538A1 (en) * | 2007-05-29 | 2010-09-30 | Yale University | IL-18 and Protein Kinase R Inhibition for the Treatment of COPD |
-
2008
- 2008-10-03 EP EP08855001A patent/EP2222297A1/en not_active Withdrawn
- 2008-10-03 AU AU2008329988A patent/AU2008329988A1/en not_active Abandoned
- 2008-10-03 RU RU2010126171/15A patent/RU2010126171A/en not_active Application Discontinuation
- 2008-10-03 CN CN200880116513A patent/CN101868235A/en active Pending
- 2008-10-03 US US12/743,312 patent/US20110077198A1/en not_active Abandoned
- 2008-10-03 MX MX2010005768A patent/MX2010005768A/en not_active Application Discontinuation
- 2008-10-03 JP JP2010534990A patent/JP2011504879A/en active Pending
- 2008-10-03 BR BRPI0819759-8A patent/BRPI0819759A2/en not_active IP Right Cessation
- 2008-10-03 WO PCT/US2008/078667 patent/WO2009070378A1/en active Application Filing
- 2008-10-03 CA CA2706656A patent/CA2706656A1/en not_active Abandoned
- 2008-10-24 TW TW097141111A patent/TW200924744A/en unknown
- 2008-11-25 AR ARP080105117A patent/AR069479A1/en unknown
- 2008-11-26 CL CL2008003524A patent/CL2008003524A1/en unknown
-
2010
- 2010-06-25 ZA ZA2010/04528A patent/ZA201004528B/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2008329988A1 (en) | 2009-06-04 |
EP2222297A1 (en) | 2010-09-01 |
US20110077198A1 (en) | 2011-03-31 |
ZA201004528B (en) | 2011-11-30 |
WO2009070378A1 (en) | 2009-06-04 |
JP2011504879A (en) | 2011-02-17 |
RU2010126171A (en) | 2012-01-10 |
AR069479A1 (en) | 2010-01-27 |
CA2706656A1 (en) | 2009-06-04 |
CL2008003524A1 (en) | 2010-01-22 |
MX2010005768A (en) | 2010-06-11 |
TW200924744A (en) | 2009-06-16 |
CN101868235A (en) | 2010-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0819759A2 (en) | Compositions and methods for inhibiting ds-rna-dependent protein kinase activation and tumor growth inhibition | |
EP2200436A4 (en) | Substituted pyrimidinyl-amines as protein kinase inhibitors | |
IL206416A0 (en) | Benzofuropyrimidinones as protein kinase inhibitors | |
BRPI0812293A2 (en) | 2-OXO-3-BENZILBENZOXAZOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS METHIN KINASE INHIBITORS FOR TREATMENT TREATMENT | |
BRPI0821129A2 (en) | Methods for healing inhibition | |
BRPI0719195A2 (en) | Kinase inhibitors useful for treating myeloproliferative and other proliferative diseases | |
SI2193133T1 (en) | Imidazolothiadiazoles for use as protein kinase inhibitors | |
BRPI0716781A2 (en) | Kinase Inhibitors | |
BRPI0807717A2 (en) | KINASE INHIBITORS USEFUL FOR TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES. | |
DK3178792T3 (en) | PROCEDURE FOR DEPOSIT INHIBITION | |
HK1151291A1 (en) | 2-benzylpyridazinone derivatives as met kinase inhibitors | |
SI2042480T1 (en) | Aminoindan derivative or salt thereof | |
HK1208701A1 (en) | Means for inhibiting the expression of protein kinase | |
EP2136829A4 (en) | Kinase protein binding inhibitors | |
IL204945A0 (en) | Compositions and methods for inhibiting tumor progression | |
IL194491A0 (en) | Thiazolyldihydroindazole derivatives as protein kinase inhibitors | |
BRPI0810207A2 (en) | METHODS AND COMPOSITIONS FOR CANCER TREATMENT | |
GB0605685D0 (en) | Inhibition of tumour growth | |
GB0603522D0 (en) | Kinase inhibition | |
DK2170891T3 (en) | Pyrazolopyrimidinon kinase inhibitors | |
ZA200810573B (en) | Substituted 3-cyanopyridines as protein kinase inhibitors | |
IL197981A0 (en) | Kinase inhibitors | |
BRPI0815414A2 (en) | EGFR INHIBITOR TREATMENT MARKER | |
BRPI0821270A2 (en) | Methods for healing inhibition | |
GB0621720D0 (en) | Inhibitors of ikk- serine-threonine protein kinase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 31/553 (2006.01), A23L 33/13 (2016.01), A61K |